{"id":3485,"date":"2014-12-02T22:01:46","date_gmt":"2014-12-02T22:01:46","guid":{"rendered":"http:\/\/general-hemp.com\/?p=269"},"modified":"2014-12-02T22:01:46","modified_gmt":"2014-12-02T22:01:46","slug":"national-news-coverage-for-kannalife-sciences-inc-an-mjna-portfolio-company","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2014\/12\/02\/national-news-coverage-for-kannalife-sciences-inc-an-mjna-portfolio-company\/","title":{"rendered":"National News Coverage for KannaLife Sciences, Inc. an MJNA Portfolio Company"},"content":{"rendered":"

FDA Approved Cannabis-Based Drug Development Fuels Discussions Regarding NFL Players, Concussions, and CTE<\/strong><\/em><\/p>\n

 <\/p>\n

SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) — News of a potential NFL lawsuit settlement and KannaLife Sciences, Inc. (“KannaLife”) license from National Institutes of Health \u2013 Office of Technology Transfer (“NIH-OTT”) to develop one or more cannabinoid based drugs to treat Chronic Traumatic Encephalopathy (CTE) has fueled national attention. In addition to the attention received by KannaLife and retired National Football League (“NFL”) star Marvin Washington, now a key advisory board member and CTE spokesperson for KannaLife, there remain big questions for the NFL regarding its policy on prescription pain killers and its exclusionary policy on medicinal cannabis for use by players to reduce pain.<\/p>\n

NFL players are still facing long-term suspensions for testing positive for traces of marijuana. Oddly, at the center of another NFL controversy is the league’s policy of denial regarding repetitive concussive injury and a serious and related post traumatic syndrome called CTE. In July 2014, NIH-OTT licensed the use of the U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants” (the ‘507 Patent”) to KannaLife for commercial development of a treatment for CTE.<\/p>\n

Boston University<\/a> defines CTE as: “a progressive degenerative disease of the brain found in athletes (and others) with a history of repetitive brain trauma, including symptomatic concussions as well as asymptomatic subconcussive hits to the head.”<\/i><\/p><\/blockquote>\n

Marvin Washington, has coined the phrase that, “Football in not a contact sport, it’s a collision sport”. He has been speaking regularly on behalf of the players of his era and the more than 4,500 retired NFL players, including himself, who are involved in a lawsuit against the NFL over the debilitating effects of concussions<\/em><\/a> and CTE.<\/p>\n

Marvin Washington now advocates that cannabinoids as neuroprotectants “make the game safer” and can protect professional, recreational and child athletes \u2013 all without any psychotropic effects or impact on performance. Working together with KannaLife, Marvin Washington is hopeful that therapeutic agents will be available in the near future and it is his desire to share “proof of concept” with the NFL in order for the league to “lead the science” for its current and former players.<\/p>\n

Dean Petkanas, CEO of KannaLife Sciences, told Fox News<\/em><\/a>‘ Dr. Manny during a recent exclusive Health Talk that his company, “\u2026 plans to file an investigational new drug application with the FDA in early 2015.”<\/p>\n

Dozens of news outlets are joining the discussion and effectively increasing awareness of cannabis as a neuroprotectant with their viewers. In November alone, national media with questions for Washington and KannaLife Sciences executives on CBD included:<\/p>\n